作者
Elahe A Mostaghel, Brett T Marck, Stephen R Plymate, Robert L Vessella, Stephen Balk, Alvin M Matsumoto, Peter S Nelson, R Bruce Montgomery
发表日期
2011/9/15
期刊
Clinical cancer research
卷号
17
期号
18
页码范围
5913-5925
出版商
American Association for Cancer Research
简介
Purpose: Abiraterone is a potent inhibitor of the steroidogenic enzyme CYP17A1 and suppresses tumor growth in patients with castration-resistant prostate cancer (CRPC). The effectiveness of abiraterone in reducing tumor androgens is not known, nor have mechanisms contributing to abiraterone resistance been established.
Experimental Design: We treated human CRPC xenografts with abiraterone and measured tumor growth, tissue androgens, androgen receptor (AR) levels, and steroidogenic gene expression versus controls.
Results: Abiraterone suppressed serum PSA levels and improved survival in two distinct CRPC xenografts: median survival of LuCaP35CR improved from 17 to 39 days (HR = 3.6, P = 0.0014) and LuCaP23CR from 14 to 24 days (HR = 2.5, P = 0.0048). Abiraterone strongly suppressed tumor androgens, with testosterone (T) decreasing from 0.49 ± 0.22 to …
学术搜索中的文章
EA Mostaghel, BT Marck, SR Plymate, RL Vessella… - Clinical cancer research, 2011
